Non-GAAP earnings slipped 5% to $11.44 per share but still came in ahead of analysts’ forecasts of $10.74. ・Sales of the ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Regeneron (REGN) reports results for the ...

Regeneron (REGN) stock in focus as the company posts Q4 2025 beat as its revenue tied to Sanofi (SNY) partnership offsets headwinds to Eylea franchise. Read more here.

Analysts expect the Tarrytown, New York-based company to report quarterly earnings at $10.74 per share, down from $12.07 per share in the year-ago period. The consensus estimate for Regeneron ...

Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund returned 3.35% in the quarter, ...

Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value ...

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its fourth-quarter 2025 investor letter for the “Baird Chautauqua International and ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Regeneron (REGN) reported $3.88 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 2.5%. EPS of $11.44 for the same period compares to $12.07 a year ago.